文摘
摘要目的:澄清如果NK和NKT细胞是通过激活补体受体NMOSD。
背景:抑制终端补neuromyelitis视谱系障碍(NMOSD)使用eculizumab有助于防止复发,但具体的药物的作用机制仍不清楚。同样,遗传变异在Fcγ受体3 (FCGR3A),也称为CD16 NMOSD与结果,但免疫细胞表达那些CD16是未知的。我们比较CD16表达在免疫细胞调制补充活动自然杀伤(NK)细胞和自然杀伤t细胞(NKT)在NMOSD疾病和正常健康控制。
设计/方法:外周血细胞(PBMC) 45 NMOSD患者样本水通道蛋白4 (AQP4)免疫球蛋白,18疾病控制和19分析了正常对照组CD16体外受体表达和补充。
结果:在基线,NMOSD NKT细胞的数量增加(p < 0.001),但CD16积极的比例是低于正常和疾病控制(p = 0.0012)。NK细胞计数正常,但CD16积极的比率也明显降低(p < 0.001)。NK细胞和NKT细胞从NMOSD C5补体受体表达是远远高于正常和疾病控制(p < 0.001)。我们也评估激活标记CD69、CD83也明显高于NK和NKT细胞NMOSD病人。FCGR3A p158V / V基因型组NMOSD患者显示与激活NK细胞比例下降,和更少的比F / CD16表示NKT细胞F基因型组。
结论:我们的研究结果支持免疫发病机理模型中补体激活NK / NKT细胞移植CD16表达式,结合抗体/抗原复合物。NMOSD的上下文中,这些complement-sensitive细胞可能负责升级自身免疫活动。
披露:他没有透露博士。莱特女士没有披露。罗坍博士没有披露。保罗博士的机构已收到个人薪酬在500 - 4999美元的范围作为顾问三菱田边PC(调性)。保罗博士的机构已收到个人薪酬在500 - 4999美元的范围为奥尔胡斯大学担任顾问。保罗医生已收到个人薪酬在500 - 4999美元的范围为在科学咨询服务或数据安全监测委员会Alexion。保罗医生已收到个人薪酬在500 - 4999美元的范围为在科学咨询服务或数据安全监测委员会罗氏。保罗医生已收到个人补偿的范围0 - 499美元为科学顾问或服务为赛诺菲Genzyme数据安全监测委员会。保罗医生已收到个人薪酬在500 - 4999美元的范围为在科学咨询服务或数据安全监测委员会的联合制药公司。保罗医生已收到个人薪酬在500 - 4999美元的范围为在科学咨询服务或数据安全监测委员会CELGENE公司。 Dr. Paul has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bayer. Dr. Paul has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Dr. Paul has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for ACRELION. Dr. Paul has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Viela Bio. Dr. Paul has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Alexion. Dr. Paul has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. Dr. Paul has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Pfizter. Dr. Paul has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck Serono. The institution of Dr. Paul has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer. Dr. Levy has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Mitsubishi Pharma. Dr. Levy has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB Pharma. Dr. Levy has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi. Dr. Levy has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Levy has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon. Dr. Levy has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Levy has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier. Dr. Levy has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Various law firms. The institution of Dr. Levy has received research support from National Institutes Health.
